Yale Univ.’s Michael Kinch spent his spare time in the last year creating a massive database that encompasses the entire history of drug development in the U.S. In a series of 20 articles scheduled to be published over the next year in Drug Discovery Today, Kinch mines the data and provides historical tidbits about the history of drug development and reveals trends on how—or whether—we will get new medicines in the future.
A Univ. of Michigan (U-M) startup developing drugs to target gene fusions that drive many common cancers such as breast, colon, prostate and lung has signed a research and license agreement with a California biopharmaceutical company. OncoFusion Therapeutics Inc., an oncology discovery and development company, was co-founded in 2012 by U-M profs. Arul Chinnaiyan and Shaomeng Wang based on discoveries from their campus laboratories.
Ten years of U.S. data suggest cholesterol-lowering statins are giving patients a license to pig out. Calorie and fat intake increased among statin users during the decade—an indication that many patients might be abandoning heart-healthy lifestyles and assuming that drugs alone will do the trick, the study authors said.
A drug under clinical trials to treat tuberculosis could be the basis for a class of broad-spectrum drugs that act against various bacteria, fungal infections and parasites, yet evade resistance, according to a study by Univ. of Illinois chemists and collaborators. The team determined the different ways the drug SQ109 attacks the tuberculosis bacterium and how the drug can be tweaked to target other pathogens from yeast to malaria.
A novel antiviral drug may protect people infected with the measles from getting sick and prevent them from spreading the virus to others, an international team of researchers says. The team of researchers developed the drug and tested it in animals infected with a virus closely related to one that causes the measles. As reported, virus levels were significantly reduced when infected animals received the drug by mouth.
Scientists have solved a decades-old medical mystery, and in the process have found a potentially less toxic way to fight invasive fungal infections, which kill about 1.5 million people a year. The researchers say they now understand the mechanism of action of amphotericin, an antifungal drug that has been in use for more than 50 years even though it is nearly as toxic to human cells as it is to the microbes it attacks.
When considering potential drug delivery vehicles, liposomes are an important option and have already been approved for use with a number of therapeutic formulations. Liposomes are comprised of phospholipids and may be single- or multi-layered, can be produced in different sizes and have a hydrophilic interior and hydrophobic shell. They are biodegradable, non-toxic and capable of encapsulating both hydrophilic and hydrophobic materials.
Nanotechnology has unlocked new pathways for targeted drug delivery, including the use of nanocarriers that can transport cargoes of small-molecule therapeutics to specific locations in the body. Researchers have recently demonstrated that processing can have significant influence on the size of nanocarriers for targeted drug delivery. It was previously assumed that once a nanocarrier is created, it maintains its size and shape anywhere.
Delivering chemotherapy drugs in nanoparticle form could help reduce side effects by targeting the drugs directly to the tumors. In recent years, scientists have developed nanoparticles that deliver one or two chemotherapy drugs, but it has been difficult to design particles that can carry any more than that in a precise ratio. Now Massachusetts Institute of Technology chemists have devised a new way to build such nanoparticles.
Builders and factory workers know that getting a job done right requires precision and specialized tools. The same is true when you’re building antibiotic compounds at the molecular level. New findings from North Carolina State Univ. may turn an enzyme that acts as a specialized “wrench” in antibiotic assembly into a set of wrenches that will allow for greater customization.
Scientists have published the first study explaining in detail how viruses reprogram the metabolism of the cells they invade to promote continued viral growth within an organism.
Pharmaceutical researchers in California, in collaboration with materials scientists, engineers and neurobiologists, have discovered a new mechanism for using near-infrared light to activate polymeric drug-delivering nanoparticles and other targeted therapeutic substances inside the body. This discovery represents a major innovation; up to now only a handful of strategies using light-triggered release from nanoparticles have been reported.
Novartis said it's cutting off late-stage research into a potential chronic heart failure treatment because the drug has proven so effective, sending shares to an all-time high when markets opened Monday. Patients taking its twice-daily pill labeled LCZ696 lived longer without being hospitalized for heart failure than those who received a standard of care, Novartis said.
Call it “homo minutus”. A team at Los Alamos National Laboratory is developing four human organ constructs (liver, heart, lung and kidney) that will work together to serve as a drug and toxicity analysis system that can mimic the actual response of human organs. Called ATHENA, for Advanced Tissue-engineered Human Ectypal Network Analyzer, the system will fit neatly on a desk.
A new microfluidic method for evaluating drugs commonly used for preventing heart attacks has found that while aspirin can prevent dangerous blood clots in some at-risk patients, it may not be effective in all patients with narrowed arteries. The study, a first in the examination of heart attack prevention drugs, used a device that simulated blood flowing through narrowed coronary arteries to assess effects of anti-clotting drugs.
AMSBIO has announced the launch of ClioCell, an ex vivo device for removal of dying and dead cells, improving viability and quality of cell populations and their subsequent productivity. The system comprises super-paramagnetic nanoparticles which have been coupled with proprietary elements that bind to dead and dying cells and cell debris.
Small protein fragments, also called peptides, are promising as drugs because they can be designed for very specific functions inside living cells. Insulin and the HIV drug Fuzeon are some of the earliest successful examples, and peptide drugs are expected to become a $25 billion market by 2018. However, a major bottleneck has prevented peptide drugs from reaching their full potential.
Scientists in the U.K. have proposed a new computer-based method of screening drugs that could be used to slow the aging process in humans. The proposed method uses gene expression data from “young” and “old” tissues to construct the cloud of molecular signalling pathways involved in ageing and longevity. It then evaluates the effects of a large number of drugs and drug combinations to emulate a youthful state for cells and tissues.
Pfizer Inc. said Wednesday that its blockbuster vaccine against pneumonia, blood and other infections met its goal of preventing illness in vulnerable elderly patients in a huge study required by U.S. regulators. The New York-based company's Prevnar 13 protects against 13 strains of pneumococcal disease, which can cause painful children's ear infections, pneumonia and life-threatening bloodstream infections.
A faster and less expensive form of radiotherapy for treating prostate cancer may come at a price, according to a new study by Yale School of Medicine researchers—a higher rate of urinary toxicity or urine poisoning. The standard therapy for prostate cancer is called intensity modulated radiation therapy (IMRT). Stereotactic body radiotherapy (SBRT) is a newer treatment that delivers a greater dose of radiation than IMRT.
A team of Univ. of Notre Dame researchers have discovered a new class of antibiotics to fight bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and other drug-resistant bacteria. Called oxadiazoles, the new class was discovered through in silico (by computer) screening and has shown promise in the treatment of MRSA in mouse models of infection.
Scientists have modified genes in the blood cells of HIV patients to help them resist the AIDS virus, and say the treatment seems safe and promising. The results give hope that this approach might one day free at least some people from needing medicines to keep HIV under control, a form of cure.
A second baby born with the AIDS virus may have had her infection put into remission and possibly cured by very early treatment—in this instance, four hours after birth. Doctors revealed the case Wednesday at an AIDS conference in Boston. The girl was born in suburban Los Angeles last April, a month after researchers announced the first case from Mississippi.
Gathering all analytical data from different techniques for the same sample isn’t always an easy and routine task. This problem is amplified in high-throughput environments based on sheer volume alone. Review and analysis of information can be time consuming, leading to delays in decision-making that have detrimental effects on productivity and the speed of project completion.
A new Yale Univ. study indicates that cell-to-cell transmission of HIV particles contributes to the development of full-blown AIDS and helps predict which anti-retroviral therapies will be most effective at keeping the disease at bay. The new research reinforces recent findings that a heavy concentration of the virus at the point of contact between cells is crucial to the development of AIDS.